Wells sees potential upside after Glaukos’ iDose repeat dosing label approved

Wells Fargo notes that Glaukos (GKOS) has announced FDA approval of its repeat dosing label for iDose, in line with the firm’s expectations. Label appears broad though with some corneal-safety limits. Overall, Wells views this as supportive of the long-term iDose annuity model. The firm has an Overweight rating on the shares with a price target of $122.